A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

This phase I trial studies the best dose and side effects of the VSV-hIFNβ-NIS vaccine with or without cyclophosphamide and combinations of ipilimumab, nivolumab, and cemiplimab in treating patients with multiple myeloma, acute myeloid leukemia or lymphoma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). VSV-IFNβ-NIS is a modified version of the vesicular stomatitis virus (also called VSV). This virus can cause infection and when it does it typically infects pigs, cattle, or horses but not humans. The VSV used in this study has bee

Trial Details

NCT ID

NCT03017820

Phase

PHASE1

Sponsor

Mayo Clinic

Status

RECRUITING

Cancer Type

Relapsed/Refractory Multiple Myeloma

Interventions

Biopsy Procedure
Biospecimen Collection
Bone Marrow Biopsy
Computed Tomography
Cyclophosphamide
Positron Emission Tomography

Locations (sample)

Scottsdale, Arizona, United States|33.50921,-111.89903
Rochester, Minnesota, United States|44.02163,-92.4699

Key Eligibility Criteria

Age \>= 18 years
Relapsed or refractory disease as follows:
Groups A, B, C or D: Multiple myeloma (MM) previously treated with an immunomodulatory imide drug (IMID), a proteosome inhibitor, and an alkylating…
All Groups except D: Relapsed peripheral T-cell lymphoma (PTCL) of the following histologies: peripheral T-cell lymphoma-NOS (PTCL-NOS); angioimmun…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →